Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Posts Tagged ‘bioscience’

Halo Collective Provides Update on Bophelo Bioscience

Posted by fidest press agency su martedì, 9 marzo 2021

Toronto, Ontario. Halo Collective Inc. (“Halo” or the “Company”) (NEO: HALO) (OTCQX: HCANF) (Germany: A9KN) provides a comprehensive update about Bophelo Bioscience & Wellness (Pty) Ltd. (“Bophelo”) — the Company’s wholly-owned subsidiary which is operating a 200-hectare cannabis site near Mafetang in Lesotho, Africa. Bophelo quadrupled the amount of cultivation space in the last year, despite the site’s depletion of necessary imported goods for its development resulting from the current climate of the COVID-19 pandemic. Specifically, the Bophelo operations expanded from 5,400 square feet to over 21,000 square feet of flowering canopy. Currently, this year’s harvest is expected to yield 750 kilograms of product, selling 1,000 kilograms this year. As part of Bophelo’s upward trajectory, it is expected the buildout for flowering canopy will reach up to 1.2 hectares this year with further plans to expand to up to 2.2 hectares by the end of 2022.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Halo Labs Provides Updates on Bophelo Bioscience and MedCan Partnership

Posted by fidest press agency su mercoledì, 20 gennaio 2021

Toronto. Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO) (OTCQX: AGEEF) (Germany: A9KN) is pleased to provide updates on recent developments with respect to Bophelo Bioscience & Wellness (Pty) Ltd. (“Bophelo”) in Lesotho, South Africa and MedCan Ltd., the Company’s Malta offtake partner (“MedCan”). Bophelo continues to operate during the COVID-19 pandemic with special approval from the local police. The first of three planned 2021 crops is already underway with a quarter of the summer harvest in the ground; 1,983 clones have filled 500 square meters of canopy. Bophelo anticipates planting 6,000 autoflower plants to fill an additional 2,000 square meters of hoop houses by the end of January 2021. By April 2021, Bophelo expects the harvest to yield approximately 800 kilograms of trimmed flower and 800 kilograms of material to produce medicinal cannabis oils. Bophelo plans to plant second and third crop within 2021.To support a planned year-round perpetual harvest and future exports to MedCan, Bophelo has also launched a Mother Program with diverse strains including those from OG DNA Genetics. Currently, 40 mother plants across ten strains are thriving. Bophelo plans to grow the mother stock to 150 plants across more strains by continuing the strain hunt. In addition, Louisa Mojela, Chair of the Board of Halo and well-known benefactor of the Lesotho community, has developed a recruitment program for local women to enter the Bophelo workforce to receive training in leading the day-to-day growing operations. The Company plans to recruit and train 30 leads with a focus on women empowerment and build a talent pool capable of sustaining operations.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Halo Provides an Update on Bophelo Bioscience

Posted by fidest press agency su sabato, 26 settembre 2020

Toronto, Ontario – Halo Labs Inc. (“Halo” or the “Company”) is pleased to provide an update in respect of recent developments for Bophelo Bioscience; Wellness (Pty) Ltd. (“Bophelo”) in Lesotho, an indirect wholly-owned subsidiary of Halo. Bophelo intends to operate one of the largest-cannabis cultivation sites in the world, and is expected to cultivate and distribute high-quality cannabis, derived from exclusive, proprietary genetics under license from OG DNA Genetics (“DNA”). The Company is also pursuing a similar license arrangement with Terphogz, cultivator of the Zkittlez cannabis strains. As previously announced, Bophelo has entered into an offtake agreement with Medcan Ltd. (“Medcan”), located in Malta, that it intends to leverage upon the receipt of a Good Agricultural and Collection Practices (“GACP“) certification. The Company is pleased to announce that Andreas Met, Chief Operating Officer and Co-Founder of Halo, will be leading Halo’s international business operations, and is planning to relocate to Lesotho by the end of 2020. Mr. Met will be tasked with three priorities:Expanding Bophelo’s operation to deliver the highest-quality product at scale.Establishing Halo’s international distribution base, first in Malta in partnership with Medcan.Selling to a broad base of potential countries in the EU, including the UK.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Halo Completes Signing of Definitive Agreement to Acquire Bophelo Bioscience

Posted by fidest press agency su sabato, 30 novembre 2019

Toronto, Ontario. Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has signed a definitive acquisition agreement with respect to its proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd (“Bophelo”) in exchange for 40,786,667 common shares of Halo (the “Transaction”).Located in the Kingdom of Lesotho, Southern Africa, Bophelo has the country’s largest licensed land area for cultivation of medicinal grade cannabis products. Bophelo currently leases a 5-hectare fully licensed greenhouse canopy, and has conditional approval to expand to an additional 200 hectares of licensed outdoor canopy. Halo expects to start exporting cannabis grown at Bophelo in Q2 2020. In total, once fully implemented, the 205-hectare Bophelo site is expected to be one of the largest cannabis cultivations in the world.
Bophelo Bioscience is based in the Kingdom of Lesotho, Southern Africa, in the Mafeteng Region. Bophelo is the holder of one of a limited number of operational licenses issued in Lesotho for the production and export of medicinal cannabis products. As the largest licensed landholder in Lesotho, Bophelo’s 9-year license allows it to cultivate, manufacture, import and export cannabis products. Situated approximately 70 kilometres from the capital city of Maseru, Bophelo’s operating site is in an ideal location with ample labor, abundant free water, flat land, and low electricity costs. The favorable high altitude and low humidity climate provide clean, organic growing conditions in this pristine mountainous region. With over 200 days of annual sunshine, Bophelo can support as many as 3 full growing seasons a year.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Michael A. Cusanovich Arizona Bioscience Educator of the Year

Posted by fidest press agency su domenica, 29 settembre 2019

The Arizona Bioindustry Association (AZBio) today announced that Marti Lindsey, PhD, community engagement director for the Southwest Environmental Health Sciences Center at the University of Arizona College of Pharmacy and director of the KEYS High School Student Internship program at the UA BIO5 Institute, will be honored as the Michael A. Cusanovich Arizona Bioscience Educator of the Year at the AZBio Awards on Oct. 2, 2019.“Learning opportunities are all around us,” stated Joan Koerber-Walker, president and CEO of AZBio. “Many of these opportunities are thanks to dedicated educators who work to make them engaging, enlightening and memorable. They help us understand the world we live in today and provide tools we can use to shape our tomorrows. Dr. Marti Lindsey is a great example of an educator who is making a difference here in Arizona and across the Southwest region.”
Each year, the Michael A. Cusanovich Arizona Bioscience Educator of the Year Award honors an educator who, as a member of the faculty or administration of an educational institution, demonstrated the greatest leadership, creativity and/or actions to inspire students and encourage them in the biosciences. In 2019, the award will honor Marti Lindsey, PhD, for a body of work spanning over 18 years at the UA.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Martha A. Brumfield, PhD, Named Arizona Bioscience Leader of the Year

Posted by fidest press agency su sabato, 21 settembre 2019

The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumfield, PhD, Special Advisor to the CEO and past President and CEO at the Critical Path Institute (C-Path), will be honored as the Jon W. McGarity Arizona Bioscience Leader of the Year at the 2019 AZBio Awards on October 2, 2019, at the Phoenix Convention Center.“You probably know someone who is waiting for a cure. Most of us do. It can take over 15 years and a billion dollars or more to bring a new life-saving or life-changing treatment to the people who are waiting for it,” shared AZBio President and CEO Joan Koerber-Walker. “Throughout her career, Dr. Brumfield has worked to bring new, safe, and effective treatments to market for patients who are waiting.”
The AZBio Awards takes place on the evening of October 2, 2019 at the Phoenix Convention Center. Highlights of the evening will include honoring the honorable Jane Dee Hull, 20th Governor of the State of Arizona with the AZBio Pioneer Award for Lifetime Achievement and a celebration of the achievements of leading researchers, educators, and innovator companies. The Life Science Fiesta following the award ceremony features a Student Discovery Zone that showcases the work of fifty students from Arizona high schools, community colleges, and universities along with exhibits featuring Arizona companies and patient advocacy organizations.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Acerus and Aytu Bioscience to Co-promote Natesto® in the United States

Posted by fidest press agency su giovedì, 1 agosto 2019

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (NASDAQ: AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men’s Health experience to capture a significant share of the U.S. market for NATESTO®. Under the terms of the new agreement, Aytu returns the NDA for NATESTO® in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies’ joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel). Aytu will retain its primary care sales force (Aytu Sales Channel) and will continue to book all product net revenue while serving as the exclusive U.S. supplier of NATESTO® to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels.To establish a high performing commercial footprint in the U.S., Acerus has engaged Syneos Health (NASDAQ: SYNH), a leading integrated biopharmaceutical solutions organization including the industry’s largest Contract Commercial Organization (CCO), to be its commercialization partner. Syneos Health has extensive experience in Men’s Health and with NATESTO®, and offers an end-to-end model that will enable Acerus to rapidly stand up a U.S. commercial team; to scale across all aspects of commercialization, including medical and regulatory affairs, managed markets, marketing and sales; and will provide greater flexibility and effectiveness in resource deployment.Low testosterone is estimated to affect approximately 39% of men over 45 years old in the U.S.; however, because the condition is underdiagnosed the overall prevalence is uncertain1. While patients have access to other treatment options, NATESTO® is unique in that it is administered in seconds via a convenient and simple nasal gel applicator, addressing the risk of testosterone transference associated with other topical products, which carry “black box” warnings on their product labels.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Twist Bioscience to Present at the UBS Global Healthcare Conference

Posted by fidest press agency su sabato, 18 Maggio 2019

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20th at 11:30 a.m. ET.This presentation will be webcast live and can be accessed by visiting the “Presentations” page of the investor relations section of the company’s website here. A replay of the presentation will be archived for a period of 90 days following the conclusion of the live event.
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Lumen Bioscience Announces Issuance of US Patent for Genetic Modification of Spirulina

Posted by fidest press agency su mercoledì, 28 novembre 2018

Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, announced today that the U.S. Patent and Trademark Office has issued Patent No. 10,131,870, entitled “Targeted Mutagenesis in Spirulina.”
Spirulina is a photosynthetic microalgae consumed all over the world, from U.S. grocery outlets to remote locations in Africa, because of its high nutritional content, safety, and ease of cultivation. It’s also widely used as an animal feedstock, and is being developed as a food for astronauts to grow in space. It is the only microorganism farmed at commercial scale worldwide.Like many single-cell organisms Spirulina reproduces asexually, which means that it is not possible to improve it by using traditional plant breeding approaches. Despite intense effort, and widespread recognition of its potential importance, Spirulina has resisted all attempts to enhance its biology using biotechnology tools that are widely used in drug development for other biological systems such as yeast and CHO. As a consequence, essentially no work has been done to improve the productivity or nutritional profile of this inexpensive, vitamin-rich protein source, nor has the opportunity to use Spirulina for synthesis of high-value products been realized.With the issuance of this patent, Lumen’s researchers now announce that they have developed a novel set of bioengineering tools and methods that finally allow researchers to introduce targeted, highly stable genetic modifications into Spirulina. The breakthrough opens the door to converting this global foodstock into a platform for producing a wide range of novel chemical and biologic products, especially medical therapeutics and vaccines.
With Lumen’s technology, researchers can now edit or remove existing Spirulina genes, or insert completely new genes directly into any desired location in the Spirulina chromosome, and see those changes persist indefinitely. Lumen itself is using this new technology to develop high-value proteins and other molecules for foods, cosmetics, medicine, and industry.
For drug development, this means faster timelines, higher chances of clinical success, and lower costs compared to traditional production systems. While tremendously successful for many applications, these older workhorses of the biotechnology industry have proven unsuitable for the large-scale production of certain classes of proteins and other biologics. Moreover, the cost of producing therapeutics in Spirulina is 100-fold less expensive than previously possible using the older biotechnology platforms. The new Spirulina platform is also a significant advance over plant-based biotechnology platforms that have been evaluated in the past, that have failed to gain commercial traction despite showing initial promise. Spirulina can make 100 times more active therapeutic protein than food crop or tobacco plant-based expression systems and the resulting drugs can be administered without expensive processing and purification. This makes the Lumen Spirulina platform an ideal system for making orally delivered biologics such as antibody therapeutics, a long-felt unmet need in healthcare.The great potential of Lumen’s technology has already led to collaborative efforts with groups all over the world, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several leading U.S. research universities, to address such critical targets as ultra-low-cost antibody therapeutics for children in developing countries, oral vaccines against infectious viruses, and other new biologics. Among other programs, Lumen announced earlier this year that the NIH had awarded Lumen a grant to develop a new oral malaria vaccine that will not require refrigerated distribution, and also previously announced that the USDA awarded another grant to Lumen to develop an oral vaccine for farmed fish.To date, Lumen has been granted 20 composition of matter and pathway patents, and 41 new applications are currently pending, all of which relate to novel approaches to engineering Spirulina and other cyanobacteria to create novel bio-based products. The new patent announced today also covers the proprietary strains used to produce Lumen’s first product, RioBlueTM, which is a natural replacement for the petroleum-derived, artificial food color called “FD&C Blue #1.” Lumen produces RioBlue in its state-of-the-art cGMP production facility in Seattle, Washington. The broad composition-of-matter claims in the patent announced today cover all engineered versions of this micro-organism, and therefore indirectly cover all of Lumen’s planned biologics products.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Heather Bimonte-Nelson, PhD of Arizona State University is the 2018 Arizona Bioscience Educator of the Year

Posted by fidest press agency su mercoledì, 26 settembre 2018

The Arizona Bioindustry Association (AZBio) today announced that Arizona State University Department of Psychology Professor Heather Bimonte-Nelson, PhD has been named the Michael A. Cusanovich Arizona Bioscience Educator of the Year. Dr. Bimonte-Nelson will be honored by Arizona’s bioscience and business communities for the diverse and innovative ways that she has inspired students of all ages at the 2018 AZBio Awards on October 3, 2018 at the Phoenix Convention Center.Heather Bimonte-Nelson had an idea 9 years ago to bring Neuroscience to 3rd graders who might not ever encounter advanced psychology. From that brainchild, the ASU Brain Fair for Children was born.Her message to the students, “Knowledge is power. You can do anything in the world that you set your mind to! If you work hard in school, you can come to Arizona State University, you can go to college, you can be a scientist!”Over the last decade, this program has offered over 7,000 third through fifth graders an understanding about the wonders of the brain, science, and the advantages of pursuing college. The Brain Fair for Children, run through the ASU Department of Psychology, with efforts from faculty, staff, and students have also brought more than 2,000 children to ASU, most from Title I schools in the Valley. Their goal: to show students that education gives them the power to decide their futures.Heather Bimonte-Nelson, PhD is a professor in the behavioral neuroscience program in the Department of Psychology at Arizona State University, the Co-Director of the Research Education Component of the Arizona Alzheimer’s Disease Core Center, and an active member of the Arizona Alzheimer’s Consortium. Her most prized role as a scientist is mentor and teacher; she has mentored over a dozen doctoral students and over 100 high school and undergraduate students in her laboratory. Bimonte-Nelson’s goal in mentoring students is to help them find their science passion, to learn that the truth in nature drives exemplary scientific discovery, and to attain the knowledge that it is more important to be honest, use your voice, and be brave, than it is to be perfect.For more than two decades, Bimonte-Nelson has conducted preclinical evaluations of multiple domains of cognitive function as related to aging, with a special focus on transitional and surgical menopause, and exogenous and endogenous hormone exposures across the lifespan. She has published more than 70 peer reviewed manuscripts evaluating hormone effects on the brain and behavior from early development until old age, with her earlier work showing that female brain organization is actively feminized by estrogens, and that estrogen exposures across the lifespan impact the female phenotype. The overarching goal of her research is to optimize the health of women into old age, encompassing discovery of menopause and hormone therapy lifetime trajectories to attain this mission. Moreover, she recently edited a book on the behavioral neuroscience of learning and memory.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Arcus Biosciences Announces Participation at Upcoming Investor Conference

Posted by fidest press agency su mercoledì, 30 Maggio 2018

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA. Individuals may access the live audio webcast by visiting the “Events & Presentations” section of the Company’s website at A replay of the webcast will be available for 30 days following the live event.Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. For more information about Arcus Biosciences, please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Alltech Acquires State-of-the-Art Algae

Posted by fidest press agency su domenica, 26 settembre 2010

[Lexington, Kentucky] – Alltech Inc. a global leader in natural animal nutrition based in Nicholasville, Kentucky, announced today that it has acquired a state-of-the-art algae fermentation facility in Winchester, Kentucky from Martek Bioscience Corporation for approximately $14 million.  Algae are some of the fastest growing plants in nature and have the ability to convert large amounts of carbon dioxide into oxygen, a characteristic that makes it particularly interesting in today’s more environmentally conscious world.  The facility will allow for continued work with Alltech’s carbon dioxide sequestering algae strains as well as strains that are grown with other carbon sources. The algae will then be used for value-added feed products, algae derived bio-fuel, and the production of ethanol.  The laboratory and pilot plant fermentation facilities in the acquisition are of particular interest as they will allow for quick product and process development. The automated control and monitoring systems on the fermenters will allow Alltech to make advances in new and current fermentation processes. One of the main focuses of the facility will be the development of products derived from algae.  Autotrophic algae require CO2, water, nutrients and sunlight during biomass growth. Each 100 tons of algal biomass fixes about 183 tons of CO2. Heterotrophic algae, which cannot use photosynthesis to generate its own food, can be grown in large closed tank systems present in the Winchester facility. Algae biomass is mainly composed of lipids, proteins and starches. The composition is dependent on the strain as well as growth conditions and can vary greatly. Fat content can range from 2% to as high as 84%. Protein content can range from 5%-70% and starch from 5%-50%. Visit the official site of the Alltech FEI World Equestrian Games at
Founded in 1980, Alltech is a leader in animal health and nutrition. With more than 2300 employees in 120 countries, the company has developed a strong regional presence in Europe, North America, Latin America, the Middle-East, Africa and Asia. The company is privately held and revenues will surpass $500 million in 2010. Alltech’s core competence lies in researching, developing and marketing natural products that are scientifically proven to enhance animal health and performance. The company is the largest producer of protected organic minerals in the world and primary in yeast, algae, and solid state fermentation systems. For further information, visit

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »